medigraphic.com

2018, Number 6

<< Back Next >>

Cir Cir 2018; 86 (6)

Ano-rectal neuroendocrine tumour: from a polyp with a good prognosis to a lethal carcinoma

De Andrés-Asenjo B, Ortiz de Solórzano-Aurusa FJ, Borrego-Pintado H, Blanco-Antona F, Romero-de Diego A, Beltrán de Heredia-Rentería J

Language: Spanish
References: 51
Page: 515-521
PDF size: 429.58 Kb.


ABSTRACT

Background: Although rectal neuroendocrine tumours are rare neoplasms, their incidence is increasing in the last three decades. The objective of this work is to study the behaviour of these tumours based on their clinical, diagnostic, therapeutic, and pathological variables in a tertiary hospital. Method: Retrospective study of rectal neuroendocrine tumours from 2000 to 2017 in our hospital. A computerized search was performed in the SNOMED program of the pathological anatomy service, using the criteria “neuroendocrine tumour” and “carcinoid tumour”. Results: We found 16 patients with ano-rectal neuroendocrine tumour; 75% were male. The median age was 53 years (range: 34-83). The diagnosis was incidental in 62.5%, with endoscopic treatment in 13 patients (81%) and surgical treatment in 3 (19%). 75% of the lesions were T1. 68.7% of the tumours showed a degree of G1 aggression. The mean follow-up was 29 months; no recurrences. During follow-up, three patients died (18.5%), all of them with metastatic G3 tumour and the mean survival was 8 months. Conclusions: The rectal neuroendocrine tumours are increasingly frequent and present variable patterns, whose prognosis will depend on their histological aggressiveness. The increase incidence may be due to a greater awareness of the existence of these tumours, to colorectal cancer screening, to the increase in the number of colonoscopies performed and to the generalization of histological studies with neuroendocrine markers.


REFERENCES

  1. Lubarsch O. Uber den primaren Krebs des Ileum nebst Bemerkungen uber das gleichzeitige Vorkommen von Krebs und Tuberkulose. Virchows Arch. 1888;3:280-317.

  2. Oberndorfer S. Karzinoid Tumore des Dunndarms. Frankf Z Pathol. 1907;1:426-30.

  3. Mandair D, Caplin M. Colonic and rectal NET’s. Best Pract Res Clin Gastroenterol. 2012;26:775-89.

  4. Ramage J, Ahmed A, Ardill J, Bax N, Breen J, Caplin M, et al. Guidelines for the management of gastroentero-pancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61 6-32.

  5. Pasieka J. Carcinoids tumors. Surg Clin N Am. 2009;89:1123-37.

  6. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet J, et al. Consensus recommendations for the diagnosis and management of well- differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol. 2010; 17:49-63.

  7. Lawrence B, Gustafsson B, Chan A, Svejda B, Kidd M, Modlin I. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40:1-18.

  8. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares J, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72.

  9. Jetmore A, Ray J, Gathright J, McMullen K, Hicks T, Timmeke A. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum. 1992;35:717-25.

  10. De Mestier L, Brixi H, Gincul R, Ponchon T, Cadiot G. Updating the management of patients with rectal neuroendocrine tumors. Endoscopy. 2013;45:1039-46.

  11. Modlin I, Lye K, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-59.

  12. Modlin I, Kidd M, Latich I, Zikusoka M, Shapiro M. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717-51.

  13. García-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez J, Martínez del Prado, Alonso Orduña V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21:1794-803.

  14. Partelli S, Maurizi A, Tamburrino D, Baldoni A, Polenta V, Crippa S, et al. A review on surgery of gastro-entero-pancreatic neuroendocrine tumors. Eur J Endocrinol. 2014;171:153-62.

  15. Mani S, Modlin I, Ballantyne G, Ahlman H, West B. Carcinoids of the rectum. J Am Coll Surg. 1994;179:231-48.

  16. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117: 3332-41.

  17. UICC (International Union Against Cancer). TNM Classification of malignant tumours. 7th ed. Chichester, West Sussex, UK; Hoboken, NJ: Wiley- Blackwell; 2009.

  18. Bosman F, Carneiro F, Hruban R, Theise N, editores. WHO Classification of tumours of the digestive system. Lyon, France: IARC; 2010.

  19. Errasti J, Espín E, Reina A. Neoplasias de recto poco frecuentes. Revisión de conjunto. Cir Esp. 2014;92 579-88.

  20. Fraenkel M, Kim M, Faggiano A, Herder W, Valk G. Incidence of gastro- enteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21:153-63.

  21. McDermott F, Heeney A, Courtney D, Mohan H, Winter D. Rectal carcinoids: a systematic review. Surg Endosc. 2014;28:2020-6.

  22. Sebastián Ayala R, Concha Sierralta M, Domínguez Vera A, Canelo Ruiz P. Tumor carcinoide de ano, presentación de un caso y revisión de la literatura. Revista de la Facultad de Medicina Humana de la Universidad Ricardo Palma. 2013;1:42-5.

  23. Caplin M, Sundin A, Nillson O, Baum P, Klose K, Kelestimur F, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012;95:88-97.

  24. Fahy B, Tang L, Klimstra D, Wong W, Guillem J, Paty P, et al. Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment. Ann Surg Oncol. 2007;14:1735-43.

  25. Shields C, Tiret E, Winter D, International Rectal Carcinoid Study Group. Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg. 2010;252:750-5.

  26. Ono A, Fujii T, Saito Y, Matsuda T, Lee DT, Gotoda T, et al. Endoscopic submucosal resection of rectal carcinoid tumors with a ligation device. Gastrointest Endosc. 2003;57:583-7.

  27. Kumar A, Sidani S, Kolli K, Stahl T, Ayscue J, Fitzgerald J, et al. Transanal endoscopic microsurgery for rectal carcinoids: the largest reported United States experience. Colorectal Dis. 2012;14:562-6.

  28. Ono A, Fujii T, Saito Y, Matsuda T, Lee D, Gotoda T, et al. Endoscopic submucosal resection of rectal carcinoid tumors with a ligation device. Gastrointest Endosc. 2003;57:583-7.

  29. Zhou X, Xie H, Xie L, Li J, Fu W. Factors associated with lymph node metastasis in radically resected rectal carcinoids: a systematic review and meta-analysis. J Gastrointest Surg. 2013;17:1689-97.

  30. Attili F, Capurso G, Vanella G, Fuccio L, Delle Fave G, Costamanga G, et al. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. Dig Liver Dis. 2014;46:9-17.

  31. Fujishima H, Misawa T, Maruoka A, Yoshinaga M, Chijiiwa Y, Nawata H. Rectal carcinoid tumor: endoscopic ultrasonographic detection and endoscopic removal. Eur J Radiol. 1993;16:198-200.

  32. Koura A, Giacco G, Curley S, Skibber J, Feig B, Ellis L. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer. 1997;79:1294-8.

  33. Kim G, Kim K, Hong S, Yu E, Yang D, Jung K, et al. Clinical outcomes of rectal neuroendocrine tumors ≤10 mm following endoscopic resection. Endoscopy. 2013;45:1018-23.

  34. Imada-Shirakata Y, Sakai M, Kajiyama T, Kin T, Inoue K, Torii A, et al. Endoscopic resection of rectal carcinoid tumors using aspiration lumpectomy. Endoscopy. 1997;29:34-8.

  35. Fujishiro M, Yahagi N, Nakamura M, Kakushima N, Kodashima S, Ono S, et al. Successful outcomes of a novel endoscopic treatment for GI tumors: endoscopic submucosal dissection with a mixture of high-molecular- weight hyaluronic acid, glycerin, and sugar. Gastrointest Endosc. 2006;63:243-9.

  36. Zhong D, Shao L, Cai J. Endoscopic mucosal resection vs endoscopic submucosal dissection for rectal carcinoid tumours: a systematic review and meta-analysis. Colorectal Dis. 2012;15:283-91.

  37. Zhou X, Xie H, Xie L, Li J, Cao W, Fu W. Endoscopic resection therapies for rectal neuroendocrine tumors: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29:259-68.

  38. Onozato Y, Kakizaki S, Iizuka H, Sohara N, Mori M, Itoh H. Endoscopic treatment of rectal carcinoid tumors. Dis Colon Rectum. 2010;53:169-76.

  39. Kobayashi K, Katsumata T, Yoshizawa S, Sada M, Igarashi M, Saigenji K, et al. Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography. Dis Colon Rectum. 2005;48:285-91.

  40. Kwaan M, Goldberg J, Bleday R. Rectal carcinoid tumors: review of results after endoscopic and surgical therapy. Arch Surg. 2008;143:471-5.

  41. Park C, Cheon J, Kim J, Shin J, Jang B, Shin S, et al. Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. Endoscopy. 2011; 43:790-5.

  42. Larrad A. Síndrome carcinoide. Cir Esp. 1997;62:224-33.

  43. Smith J, Reidy D, Goodman K, Shia J, Nash G. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol. 2014;21:2956-62.

  44. Sorbye H, Strosberg J, Baudin E, Klimstra D, Yao J. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120:2814-23.

  45. Castellano D, Bajetta E, Panneerselvam A, Stephen S, Kocha W, O’Drisio T, et al. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2013;18:46-53.

  46. Kulke M, Shah M, Benson A, Bergsland E, Berlin J, Blaszkowky L, et al. Neuroendocrine tumors. Version I.J Natl Compr Canc Netw. 2015 Jan; 13(1):78-108.

  47. Escudero MP, Acha J, Alonso V, et al. TNE intestinales. Guía Práctica de Diagnóstico, Tratamiento y Seguimiento de Tumores Neuroendocrinos, Versión 3. Barcelona: EdikaMed; 2016. p. 99-120.

  48. Chagpar R, Chian Y, Xing Y, Cormier J, Feig B, Rashid A, et al. Neuroendocrine tumors of the colon and rectum: prognostic relevance and comparative performance of current staging systems. Ann Surg Oncol. 2013;20:1170-8.

  49. Kim M, Hur H, Min B, Baik S, Lee K, Kim N. Clinical outcomes for rectal carcinoid tumors according to a new (AJCC 7th edition) TNM staging system: a single institutional analysis of 122 patients. J Surg Oncol. 2013; 107:835-41.

  50. Kunz P, Reidy-Lagunes D, Anthony L, Bertino E, Brendtro K, Chan J, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557-77.

  51. Öberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro- entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2012;23:124-30.




2020     |     www.medigraphic.com